Cargando…

Changes in the Expression of TGF-Beta Regulatory Pathway Genes Induced by Vitamin D in Patients with Relapsing-Remitting Multiple Sclerosis

Vitamin D is an environmental factor related to multiple sclerosis that plays a significant role in immune regulation. TGF-β is a superfamily of cytokines with an important dual effect on the immune system. TGF-β inhibits the Th1 response while facilitating the preservation of regulatory T cells (FO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lozano-Ros, Alberto, Martínez-Ginés, María L., García-Domínguez, José M., Salvador-Martín, Sara, Goicochea-Briceño, Haydee, Cuello, Juan P., Meldaña-Rivera, Ariana, Higueras-Hernández, Yolanda, Sanjurjo-Sáez, María, Álvarez-Sala-Walther, Luis A., López-Fernández, Luis A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572771/ https://www.ncbi.nlm.nih.gov/pubmed/37833895 http://dx.doi.org/10.3390/ijms241914447

Ejemplares similares

Evolution of antibody titres against Epstein–Barr virus and human herpesvirus 6A/B and expression of multiple sclerosis-associated retrovirus in the serum of pregnant multiple sclerosis patients
por: Pérez-Pérez, Silvia, et al.
Publicado: (2021)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Relapsing/remitting type 1 diabetes
por: van Megen, Kayleigh M., et al.
Publicado: (2017)

Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis
por: Sainz de la Maza, Susana, et al.
Publicado: (2023)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study
por: Izquierdo, Guillermo, et al.
Publicado: (2017)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
por: Barrero, Francisco, et al.
Publicado: (2020)

Episodic Past, Future, and counterfactual thinking in Relapsing-Remitting Multiple sclerosis
por: Ayala, Oscar Daniel, et al.
Publicado: (2022)

A Case of Relapsing-Remitting Tumefactive Demyelination
por: Wadhwa, Ankur, et al.
Publicado: (2019)

Relapsing and remitting viral diseases of the nervous system
por: Johnson, Richard T.
Publicado: (1984)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi, Alessandra, et al.
Publicado: (2013)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015)

Differential Expression of SMAD Genes and S1PR1 on Circulating CD4+ T Cells in Multiple Sclerosis and Crohn’s Disease
por: Abarca-Zabalía, Judith, et al.
Publicado: (2020)

Altered individual behavioral and EEG parameters are related to the EDSS score in relapsing-remitting multiple sclerosis patients
por: Vázquez-Marrufo, Manuel, et al.
Publicado: (2019)

Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
por: Etta, Indu, et al.
Publicado: (2023)

Varicella Zoster Virus and Relapsing Remitting Multiple Sclerosis
por: Sotelo, Julio, et al.
Publicado: (2011)

Relapsing–remitting painful ophthalmoplegia due to orbital myositis
por: Guaschino, E., et al.
Publicado: (2005)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Abnormal multisensory integration in relapsing–remitting multiple sclerosis
por: Giurgola, Serena, et al.
Publicado: (2022)

Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism
por: Ramos-Cejudo, Jaime, et al.
Publicado: (2011)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015)

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
por: Daruwalla, Cyrus, et al.
Publicado: (2023)

Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis
por: Meijboom, Rozanna, et al.
Publicado: (2023)

Cytokines as Biomarkers of Treatment Response to IFNβ in Relapsing-Remitting Multiple Sclerosis
por: Dimisianos, Nikolaos, et al.
Publicado: (2014)

The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis
por: D’Amico, Emanuele, et al.
Publicado: (2019)

Peripheral CD39-expressing T regulatory cells are increased and associated with relapsing-remitting multiple sclerosis in relapsing patients
por: Álvarez-Sánchez, Nuria, et al.
Publicado: (2019)

Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)
por: Fernández, Oscar, et al.
Publicado: (2017)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Spinal epidural lipomatosis: An unusual cause of relapsing and remitting paraparesis
por: Rajput, Dinesh, et al.
Publicado: (2010)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
por: Romme Christensen, Jeppe, et al.
Publicado: (2012)

Defective structural RNA processing in relapsing-remitting multiple sclerosis
por: Spurlock, Charles F, et al.
Publicado: (2015)

Thalamic–hippocampal–prefrontal disruption in relapsing–remitting multiple sclerosis
por: Kern, Kyle C., et al.
Publicado: (2014)

Characterization of Remitting and Relapsing Hyperglycemia in Post-Renal-Transplant Recipients
por: Boloori, Alireza, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_88rroal6c1q15h77j72qrfbjk0